Shares of medical device company Merit Medical Systems (NASDAQ:MMSI)
jumped 4.6% in the afternoon session after Needham reiterated its "Buy" rating and a $108 price target on the stock.
The company expects second-quarter revenue to grow by as much as 14% year-over-year, with foreign exchange headwinds expected to trim approximately $2.3 million from the top line.
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on.
But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.
As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the medical devices & supplies - cardiology, neurology, vascular industry, including Merit Medical Systems (NASDAQ:MMSI) and its peers.
Medical device company Merit Medical Systems (NASDAQ:MMSI) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, with sales up 9.8% year on year to $355.4 million. The company expects the full year’s revenue to be around $1.48 billion, close to analysts’ estimates. Its non-GAAP profit of $0.86 per share was 14.8% above analysts’ consensus estimates.
Generating cash is essential for any business, but not all cash-rich companies are great investments.
Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Medical device company Merit Medical Systems (NASDAQ:MMSI) announced better-than-expected revenue in Q1 CY2025, with sales up 9.8% year on year to $355.4 million. The company expects the full year’s revenue to be around $1.48 billion, close to analysts’ estimates. Its non-GAAP profit of $0.86 per share was 14.8% above analysts’ consensus estimates.
Medical device company Merit Medical Systems (NASDAQ:MMSI)
will be announcing earnings results tomorrow after the bell. Here’s what investors should know.
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Merit Medical Systems (NASDAQ:MMSI) and the rest of the medical devices & supplies - cardiology, neurology, vascular stocks fared in Q4.
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the medical devices & supplies - cardiology, neurology, vascular industry, including Artivion (NYSE:AORT) and its peers.
Merit Medical guides below consensus on FY25 EPS, projects up to $1.49 billion revenue, and faces tariff risks amid ongoing global manufacturing expansion.
